Dirk Bottke

Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer

Combination of Adjuvant Hormonal and Radiation Therapy Significantly Prolongs Survival of Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis

Continued Benefit to Androgen Deprivation Therapy for Prostate Cancer Patients Treated With Dose-Escalated Radiation Therapy Across Multiple Definitions of High-Risk Disease

Radiation Therapy: Uveal Tumors

Manipulation of the nerve growth factor network in prostate cancer

Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Merkel cell carcinoma

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

Performance of ChatGPT on USMLE: Potential for AI-assisted medical education using large language models

The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

EAU Guidelines on Prostate Cancer

Deep learning in histopathology: the path to the clinic

Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease

Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen

Review of deep learning: concepts, CNN architectures, challenges, applications, future directions

Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Perineural invasion in cancer

Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement

Bendamustine: Rebirth of an Old Drug

Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity

Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma

Diffusion-Weighted MRI in the Body: Applications and Challenges in Oncology

Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

Cancer de la prostate

Phase 3 Study of Adjuvant Radiotherapy Versus Wait and See in pT3 Prostate Cancer: Impact of Pathology Review on Analysis

Phase I Trial of Radiochemotherapy with Bendamustine in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Potential of Radiation Therapy in the Multimodal Management of Merkel Cell Carcinoma

Salvage radiotherapy after prostatectomy – What is the best time to treat?

External beam radiotherapy of choroidal metastases – final results of a prospective study of the German Cancer Society (ARO 95-08)

Adjuvant Radiotherapy after Radical Prostatectomy: Indications, Results and Side Effects

Achieving an Undetectable PSA After Radiotherapy for Biochemical Progression After Radical Prostatectomy Is an Independent Predictor of Biochemical Outcome—Results of a Retrospective Study

Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

Phase III results of adjuvant radiotherapy (RT) versus “wait and see” (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96–02/AUO AP 09/95)

Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP)(ARO 96–02/AUO AP 09/95)